Private equity firm snaps up Parexel

Pamplona Capital's $5 billion deal for Parexel is the latest in a string of takeovers and mergers that have shaken up the contract research space.

By Suzanne Elvidge • June 21, 2017

#BIO2017 Day 1 roundup: Saunders' popularity and BI's strategy

The first day of the Biotechnology Innovation Center conference kicked off in San Diego, attracting thousands of industry participants to the sunny convention center. 

By Lisa LaMotta • June 19, 2017

Prescribed Reading: ADA, Mylan, and an executive order?

The SGLT-2 category heats up at ADA, Mylan faces pressure from all sides, and President Trump might put his stamp on drug pricing.

By Lisa LaMotta • June 16, 2017

Pfizer builds out anti-infective reach with Basilea deal

The pharma giant has picked up commercialization rights for Basilea's Cresemba in Europe, adding another product to its ex-U.S. portfolio.

By Suzanne Elvidge • June 16, 2017

New deal should help Baxter speed up generic injectables development

The agreement with Dorizoe Lifesciences covers more than 20 treatments for cancer, cardiovascular disease or infections.

By Jacob Bell • June 15, 2017

Novartis, Verily back new $300M fund for European biotechs

Investment firm Medicxi launched the new fund to address a lack of "growth capital" for European biotechs that have moved beyond early-stage research. 

By Ned Pagliarulo • June 15, 2017

JSR snaps up cell line developer

Japanese life sciences company JSR has hooked cell line developer Selexis to create a 'gene to GMP' service.

By Suzanne Elvidge • June 15, 2017

Celgene swoops in on cancer collaboration with Dragonfly

Young startup Dragonfly Therapeutics scored a major partner in a five-year collaboration aimed at bringing its natural killer cell technology to Celgene's pipeline.

By Suzanne Elvidge • June 12, 2017

Regulus reports a trio of pipeline setbacks

The maker of microRNA therapies terminated two clinical programs, including one for its lead candidate, and revealed that AstraZeneca is pulling out of development for a third candidate.

By Jacob Bell • June 12, 2017

Prescribed Reading: June filled with divestitures and data

Conference season is in full swing for the industry, big pharma is selling off assets and the FDA is making some surprising moves. 

By Lisa LaMotta • June 9, 2017

AMRI valued at $930M in takeout offer

The Carlyle Group and GTCR agreed to pay $21.75 per outstanding share of the contract research and manufacturing organization.

By Jacob Bell • June 8, 2017

Roche drops NewLink IDO inhibitor after ASCO

The big pharma is bowing out of a hot area in cancer, setting up its former biotech partner for a rough road ahead. 

By Lisa LaMotta • June 8, 2017

Lilly drops $55M for access to new class of diabetes drugs

The big drugmaker locked down worldwide rights to a handful of dual amylin calcitonin receptor agonists through a new deal with KeyBioscience.

By Jacob Bell • June 8, 2017

Valeant makes latest divestment as business unravels

The beleaguered specialty pharma is selling off another piece of its business in an attempt to pay down debt. 

By Lisa LaMotta • June 8, 2017

Kamada slumps after Shire hands back rights

Kamada investors show concern as Shire backs out of a graft-versus-host disease study. 

By Suzanne Elvidge • June 8, 2017

AstraZeneca continues deal spree, sells off latest asset

The British pharma continues monetizing non-core assets as it pushes toward lofty revenue goals.

By Lisa LaMotta • June 7, 2017

Innate gives Novo antibody new life

A deal that could be worth over $500 million gives Innate access to a Novo Nordisk antibody originally developed for arthritis.

By Suzanne Elvidge • June 5, 2017

GSK uses priority voucher to file HIV combo

The British pharma and ViiV Healthcare filed the regimen of dolutegravir and rilpivirine with U.S. and European regulators using one of the FDA's fast passes that GSK picked up recently.

By Jacob Bell • June 2, 2017

Prescribed Reading: Combos to take center stage at ASCO

On the eve of ASCO, some question the validity of certain combination testing for oncology drugs, pointing to the increased number of combo trials taking place. 

By Lisa LaMotta • June 2, 2017

Reworked deal gives Minerva cash windfall from Janssen

As a result of J&J's deal for Actelion, the pharma unit is handing rights to an insomnia candidate back to Minerva — delivering a boost to the biotech's share price.

By Suzanne Elvidge • June 2, 2017

Array and Ono hook up on two oncology drugs

Following its partnership of the cancer combo to Pierre Fabre in 2015, Array BioPharma sells off further rights for up to $188 million plus royalties in another regional deal.

By Suzanne Elvidge • June 2, 2017

Chiltern acquires Japanese CRO in Asia expansion bid

The multinational clinical services company acquired Integrated Development Associates, which has a base in Japan, Korea and Southeast Asia. 

By Ned Pagliarulo • June 1, 2017

J&J puts $1B on the line for success of Protagonist drug

Janssen now holds exclusive rights to PTG-200, a candidate for inflammatory bowel disease that should enter early-stage testing in the second half of 2017.

By Jacob Bell • May 30, 2017

Prescribed Reading: FDA on a roll, while pharma continues sell off

The regulatory agency continues its approval spree, just as big pharma sells off older assets in its ongoing restructuring. 

By Lisa LaMotta • May 26, 2017

Merck, UnitedHealth explore improving value-based contracts

The big pharma and insurer are working on a multiyear project aimed at better understanding and optimizing pay-for-performance deals.

By Jacob Bell • May 26, 2017